Radionetics Oncology
PrivateLast Round
Strategic
Jul 1, 2024
Est. Valuation
$60.61M
Total Funding Raised
$222.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Radionetics Oncology is a biopharmaceutical company that discovers and develops novel small-molecule radiopharmaceuticals targeting G-protein coupled receptors for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Radionetics Oncology Comparables
Compare Radionetics Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alpha-9 Oncology | 90% | |
| Abdera Therapeutics | 89% | |
| TwoStep Therapeutics | 86% |
Radionetics Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jul 1, 2024 | ||||
| Series A | Jan 3, 2024 | ||||
| Seed | Oct 18, 2021 |
Key People
Founding team and executive leadership
Radionetics Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Frazier Healthcare Partners | Seed |
| DCVC Bio | Series A |
| GordonMD Global Investments | Series A |
| 5AM Ventures | Series A, Seed |
| Frazier Life Sciences | Series A |
| DCVC (Data Collective) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 38% MoM, reaching 2K.
- Apr 11, 2026
Announced a strategic agreement with Eli Lilly.
Radionetics Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Radionetics Oncology's valuation, stock price, and market status.
Is Radionetics Oncology a public or private company?
Radionetics Oncology is a private company.
What is the current stock price of Radionetics Oncology?
Radionetics Oncology is a private company, so its shares have no public market price. Caplight tracks Radionetics Oncology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Radionetics Oncology worth (valuation)?
Radionetics Oncology's valuation is estimated at $60.6M based on funding round data.
Can I buy Radionetics Oncology stock?
Radionetics Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Radionetics Oncology's last funding round?
Radionetics Oncology's most recent funding round was Strategic on July 1, 2024.
Who are the main investors in Radionetics Oncology?
Key investors in Radionetics Oncology include Frazier Healthcare Partners, DCVC Bio, 5AM Ventures, Frazier Life Sciences.
Will Radionetics Oncology IPO soon?
No public IPO plans have been announced for Radionetics Oncology.
How can I track Radionetics Oncology secondary market activity?
Caplight tracks bids, offers, and trades in Radionetics Oncology's shares on secondary markets.